Safety and efficacy of a docetaxel-5FU-oxaliplatin regimen with or without trastuzumab in neoadjuvant treatment of localized gastric or gastroesophageal junction cancer: A retrospective study.

Fiche publication

Date publication

août 2019

Journal

World journal of gastrointestinal oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr FRAISSE Jean , Pr GHIRINGHELLI François , Dr VINCENT Julie , Dr BENGRINE-LEFEVRE Leila , Dr ORRY David , Dr HENNEQUIN Audrey

Tous les auteurs :
Basso V, Orry D, Fraisse J, Vincent J, Hennequin A, Bengrine L, Ghiringhelli F

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/31435464

Résumé

Triplet chemotherapy, with docetaxel-5FU-oxaliplatin FLOT regimen recently became the standard perioperative treatment for localized gastric cancer (GC). An adapted regimen called TeFOX was recently tested in metastatic setting and gave promising results.